You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神威药业(02877.HK)附属向关连方提供技术服务 代价1,400万人币
阿思达克 11-05 17:30

神威药业集团(02877.HK)公布,间接全资附属神威药业与神威医药签订一份有关由神威医药向神威药业提供服务的技术服务合同,向对方提供与项目(塞络通胶囊Ⅲ期临床试验)有关的技术服务,包括但不限於,项目管理、监查及质控项目的进度和过程,筛选中心实验室及冷链运输公司,配备参研单位及相关技术人员,监查及向技术人员及研究人员提供培训(费用由神威医药支付) ,准备及文档管理相关文件,及定期向神威药业报告,技术服务合同代价为1,400万元人民币。

公司执行董事李振江的配偶任俊英间接持有神威医药的100%权益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account